Por: RTTNews Health December 07, 2023
Sanofi () announced the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa or isatuximab in combination with standard-of-care bortezomib, lenalidomide and dexamethasone or VRd met its primary endpoint at a planned interim analysis for efficacy, showing statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma.The company said... + full article
ABC News USA Health August 04, 2023
A new immunization to protect infants from was approved by the Centers for Disease Control and Prevention on Thursday.The approved drug called nirsevimab, which will be marketed in the U.S. by Sanofi as Beyfortus, was recommended unanimously by the CDC's Advisory Committee... + más
RSV season may have already begun, CDC warns, with early activity in the Southeast | Los Angeles Times
First-ever RSV vaccine could be approved, roll out by August | New York Post
Forbes USA Business March 17, 2023
Topline Pharmaceutical giant Sanofi announced Thursday it will cut the price of its most commonly prescribed insulin by 78% and cap the monthly cost at $35, becoming the latest drug maker—behind Eli Lilly and Novo Nordisk—to slash insulin costs this month, amid growing calls... + más
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly | Forbes
How the Other Insulin Makers Are Responding to Eli Lilly’s Price Cap | Time
WPTV USA Nation March 17, 2023
Amid pressure from both the public and the Biden administration, a third insulin maker announced it is capping insulin prices. The announcement this week by Sanofi means the three largest insulin producers in the world have instituted price caps in recent... + más
Sanofi Cuts Insulin Prices Up To 78%—Following Eli Lilly And Novo Nordisk | Forbes
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35 | ABC7
CNBC USA Health March 16, 2023
A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, January 9, 2020.George Frey Reuters on Thursday said it's planning to cut the U.S. price of its most popular insulin drug by 78% and cap monthly out-of-pocket... + más
ABC News USA Health November 11, 2022
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm. The company said Thursday that the 62-year-old Viehbacher will become president and CEO... + más
Biogen tabs veteran pharma leader Viehbacher as next CEO | Associated Press
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
ABC News USA Health November 04, 2022
In what could signal the promise of progress to come for newborn infants at risk for RSV, a new monoclonal antibody is being granted approval in Europe as a preventative measure to protect against RSV infection in very young babies -- those most at risk of contracting the virus... + más
Pfizer says study shows vaccinating pregnant women protects newborns from RSV | ABC7
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
9to5Mac USA Tech October 03, 2022
After launching in 2019, to help organizations manage their Apple fleet, Kandji went to work on solving additional problems. Today, announced its new Device Harmony platform, which is aimed at bridging the gap between and InfoSec teams, so they can truly work together to keep... + más
Logitech finally makes a wireless mechanical keyboard with a true Mac layout | Ars Technica
What are all the solutions needed to run a fleet of Macs at Work? | 9to5Mac
About iurex | Privacy Policy | Disclaimer |